Rheumatoid arthritis: Preoperative evaluation for total hip and total knee replacement surgery

Journal of Clinical Rheumatology

Volumn 19, Issue 4, 2013, Pages 187-192

  Goodman, Susan M ^a  

^a Hospital for Special Surgery   (United States)

Author keywords

Preoperative evaluation; Rheumatoid arthritis; Total hip and total knee replacement

Indexed keywords

CEFAZOLIN; CLINDAMYCIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; VANCOMYCIN; WARFARIN;

ANTIBIOTIC THERAPY; ATLANTOAXIAL SUBLUXATION; CARDIOVASCULAR RISK; CERVICAL SPINE; CERVICAL SPINE DISLOCATION; COMPRESSION STOCKING; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG USE; HUMAN; INFECTION; INFECTION RISK; PERIPROSTHETIC JOINT INFECTION; PHYSIOTHERAPY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SMOKING; SMOKING CESSATION; SPINE INSTABILITY; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

ARTHRITIS, RHEUMATOID; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; CERVICAL VERTEBRAE; FOOT DEFORMITIES, ACQUIRED; HEART DISEASES; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; OPPORTUNISTIC INFECTIONS; PERIODONTAL DISEASES; PREOPERATIVE CARE; PROSTHESIS-RELATED INFECTIONS; RISK ASSESSMENT; SPINAL DISEASES; VENOUS THROMBOEMBOLISM;

EID: 84880049610     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0b013e318289be22     Document Type: Review

References (100)

1. Pincus T, Sokka T, Kautiainen H. Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum. 2005;52:1009-1019.
2. Massardo L, Gabriel SE, Crowson CS, et al. A population based assessment of the use of orthopedic surgery in patients with rheumatoid arthritis. J Rheumatol. 2002;29:52-56.
3. Kapetanovic MC, Lindqvist E, Saxne T, et al. Orthopaedic surgery in patients with rheumatoid arthritis over 20 years: prevalence and predictive factors of large joint replacement. Ann Rheum Dis. 2008;67:1412-1416.
4. Hekmat K, Jacobsson L, Nilsson JA, et al. Decrease in the incidence of total hip arthroplasties in patients with rheumatoid arthritis-results from a well defined population in south Sweden. Arthritis Res Ther. 2011;13:R67.
5. Kurtz S, Ong K, Lau E, et al. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007;89:780-785.
6. Osnes-Ringen H, Kvien TK, Henriksen JE, et al. Orthopaedic surgery in 255 patients with inflammatory arthropathies: longitudinal effects on pain, physical function and health-related quality of life. Ann Rheum Dis. 2009;68:1596-1601.
7. Soohoo NF, Farng E, Lieberman JR, et al. Factors that predict short-term complication rates after total hip arthroplasty. Clin Orthop Relat Res. 2010;468:2363-2371.
8. Bongartz T, Halligan CS, Osmon DR, et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum. 2008;59: 1713-1720.
9. Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med. 2008;121 (10 suppl 1):S3-S8.
10. Yazdanyar A, Wasko MC, Kraemer KL, et al. Perioperative all-cause mortality and cardiovascular events in patients with rheumatoid arthritis: comparison with unaffected controls and persons with diabetes mellitus. Arthritis Rheum. 2012;64:2429-2437.
11. Mameli A, Barcellona D, Marongiu F. Rheumatoid arthritis and thrombosis. Clin Exp Rheumatol. 2009;27:846-855.
12. Holmqvist ME, Neovius M, Eriksson J, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA. 2012;308:1350-1356.
13. Bohm P, Holy T, Pietsch-Breitfeld B, et al. Mortality after total knee arthroplasty in patients with osteoarthrosis and rheumatoid arthritis. Arch Orthop Trauma Surg. 2000;120:75-78.
14. Domsic RT, Lingala B, Krishnan E. Systemic lupus erythematosus, rheumatoid arthritis, and postarthroplasty mortality: a cross-sectional analysis from the nationwide inpatient sample. J Rheumatol. 2010;37:1467-1472.
15. Goodman SM, Figgie MP, Mackenzie CR. Perioperative management of patients with connective tissue disease. HSS J. 2011;7:72-79.
16. Neva MH, Hakkinen A, Makinen H, et al. High prevalence of asymptomatic cervical spine subluxation in patients with rheumatoid arthritis waiting for orthopaedic surgery. Ann Rheum Dis. 2006;65:884-888.
17. Meding JB, Keating EM, Ritter MA, et al. The planovalgus foot: a harbinger of failure of posterior cruciate-retaining total knee replacement. J Bone Joint Surg Am. 2005;87(suppl 2):59-62.
18. Keenan MA, Peabody TD, Gronley JK, et al. Valgus deformities of the feet and characteristics of gait in patients who have rheumatoid arthritis. J Bone Joint Surg Am. 1991;73:237-247.
19. Neva MH, Myllykangas-Luosujarvi R, Kautiainen H, et al. Mortality associated with cervical spine disorders: a population-based study of 1666 patients with rheumatoid arthritis who died in Finland in 1989. Rheumatology (Oxford). 2001;40:123-127.
20. Kauppi MJ, Neva MH, Laiho K, et al. Rheumatoid atlantoaxial subluxation can be prevented by intensive use of traditional disease modifying antirheumatic drugs. J Rheumatol. 2009;36:273-278.
21. Kauppi M, Neva MH. Sensitivity of lateral view cervical spine radiographs taken in the neutral position in atlantoaxial subluxation in rheumatic diseases. Clin Rheumatol. 1998;17:511-514.
22. Lopez-Olivo MA, Andrabi TR, Palla SL, et al. Cervical spine radiographs in patients with rheumatoid arthritis undergoing anesthesia. J Clin Rheumatol. 2012;18:61-66.
23. Wasserman BR, Moskovich R, Razi AE. Rheumatoid arthritis of the cervical spine-clinical considerations. Bull NYU Hosp Jt Dis. 2011;69:136-148.
24. Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med. 2008;121(10 suppl 1):S9-S14.
25. Meune C, Touze E, Trinquart L, et al. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2009;48:1309-1313.
26. Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005;52:402-411.
27. Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum. 2008;58:2612-2621.
28. del Rincon ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44:2737-2745.
29. Peters MJ, van Halm VP, Voskuyl AE, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum. 2009;61:1571-1579.
30. Lindhardsen J, Ahlehoff O, Gislason GH, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis. 2011;70:929-934.
31. Dixon WG, Watson KD, Lunt M, et al, British Society for Rheumatology Biologics Register Control Centre Consortium. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007;56:2905-2912.
32. Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:576-582.
33. Provan SA, Semb AG, Hisdal J, et al. Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Ann Rheum Dis. 2011;70:812-817.
34. Solomon DH, Kremer J, Curtis JR, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis. 2010;69:1920-1925.
35. Mantilla CB, Horlocker TT, Schroeder DR, et al. Frequency of myocardial infarction, pulmonary embolism, deep venous thrombosis, and death following primary hip or knee arthroplasty. Anesthesiology. 2002;96:1140-1146.
36. Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999;100:1043-1049.
37. Urban MK, Jules-Elysee K, Loughlin C, et al. The one year incidence of postoperative myocardial infarction in an orthopedic population. HSS J. 2008;4:76-80.
38. SooHoo NF, Lieberman JR, Ko CY, et al. Factors predicting complication rates following total knee replacement. J Bone Joint Surg Am. 2006;88:480-485.
39. Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2009;120:e169-e276.
40. Schrama JC, Espehaug B, Hallan G, et al. Risk of revision for infection in primary total hip and knee arthroplasty in patients with rheumatoid arthritis compared with osteoarthritis: a prospective, population-based study on 108,786 hip and knee joint arthroplasties from the Norwegian Arthroplasty Register. Arthritis Care Res (Hoboken). 2010;62:473-479.
41. Ravi B, Escott B, Shah PS, et al. A systematic review and meta-analysis comparing complications following total joint arthroplasty for rheumatoid arthritis versus for osteoarthritis. Arthritis Rheum. 2012; 64:3839-3849.
42. Del Pozo JL, Patel R. Clinical practice. Infection associated with prosthetic joints. N Engl J Med. 2009;361:787-794.
43. Marculescu CE, Osmon DR. Antibiotic prophylaxis in orthopedic prosthetic surgery. Infect Dis Clin North Am. 2005;19:931-946.
44. Jamsen E, Huhtala H, Puolakka T, et al. Risk factors for infection after knee arthroplasty. A register-based analysis of 43,149 cases. J Bone Joint Surg Am. 2009;91:38-47.
45. Jamsen E, Varonen M, Huhtala H, et al. Incidence of prosthetic joint infections after primary knee arthroplasty. J Arthroplasty. 2010;25:87-92.
46. Peersman G, Laskin R, Davis J, et al. Infection in total knee replacement: a retrospective review of 6489 total knee replacements. Clin Orthop Relat Res. 2001;15-23.
47. Peel TN, Dowsey MM, Daffy JR, et al. Risk factors for prosthetic hip and knee infections according to arthroplasty site. J Hosp Infect. 2011;79:129-133.
48. Walsh M, Preston C, Bong M, et al. Relative risk factors for requirement of blood transfusion after total hip arthroplasty. J Arthroplasty. 2007;22:1162-1167.
49. Au K, Reed G, Curtis JR, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:785-791.
50. Scher JU, Ubeda C, Equinda M, et al. Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. Arthritis Rheum. 2012;64:3083-3094.
51. Smit MD, Westra J, Vissink A, et al. Periodontitis in established rheumatoid arthritis patients: a cross-sectional clinical, microbiological and serological study. Arthritis Res Ther. 2012;14:R222.
52. Jackson MS, Bagg J, Gupta MN, et al. Oral carriage of staphylococci in patients with rheumatoid arthritis. Rheumatology (Oxford). 1999;38:572-575.
53. Jacobson JJ, Patel B, Asher G, et al. Oral staphylococcus in older subjects with rheumatoid arthritis. J Am Geriatr Soc. 1997;45:590-593.
54. Bassetti S, Wasmer S, Hasler P, et al. Staphylococcus aureus in patients with rheumatoid arthritis under conventional and anti-tumor necrosis factor-alpha treatment. J Rheumatol. 2005;32:2125-2129.
55. Berbari EF, Osmon DR, Duffy MC, et al. Outcome of prosthetic joint infection in patients with rheumatoid arthritis: the impact of medical and surgical therapy in 200 episodes. Clin Infect Dis. 2006;42:216-223.
56. Kallberg H, Ding B, Padyukov L, et al. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis. 2011;70:508-511.
57. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet. 2009;373:659-672.
58. Bierbaum BE, Callaghan JJ, Galante JO, et al. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am. 1999;81:2-10.
59. Innerhofer P, Klingler A, Klimmer C, et al. Risk for postoperative infection after transfusion of white blood cell-filtered allogeneic or autologous blood components in orthopedic patients undergoing primary arthroplasty. Transfusion. 2005;45:103-110.
60. Pedersen AB, Mehnert F, Overgaard S, et al. Allogeneic blood transfusion and prognosis following total hip replacement: a population-based follow up study. BMC Musculoskelet Disord. 2009;10:167, 2474-10-167.
61. Schwarzkopf R, Chung C, Park JJ, et al. Effects of perioperative blood product use on surgical site infection following thoracic and lumbar spinal surgery. Spine (Phila Pa 1976). 2010;35:340-346.
62. Hatzidakis AM, Mendlick RM, McKillip T, et al. Preoperative autologous donation for total joint arthroplasty. An analysis of risk factors for allogenic transfusion. J Bone Joint Surg Am. 2000;82:89-100.
63. Nikolaisen C, Figenschau Y, Nossent JC. Anemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality. J Rheumatol. 2008;35:380-386.
64. Bloxham E, Vagadia V, Scott K, et al. Anaemia in rheumatoid arthritis: can we afford to ignore it? Postgrad Med J. 2011;87:596-600.
65. Kendoff D, Tomeczkowski J, Fritze J, et al. Preoperative anemia in orthopedic surgery: clinical impact, diagnostics and treatment. Orthopade. 2011;40:1018, 1020, 1023-1025, 1027-1028.
66. Delasotta LA, Rangavajjula AV, Frank ML, et al. The use of epoetin-alpha in revision knee arthroplasty. Adv Orthop. 2012;2012:595027.
67. Kim S, Altneu E, Monsef JB, et al. Nonanemic patients do not benefit from autologous blood donation before total knee replacement. HSS J. 2011;7:141-144.
68. Shourt CA, Crowson CS, Gabriel SE, et al. Orthopedic surgery among patients with rheumatoid arthritis 1980-2007: a population-based study focused on surgery rates, sex, and mortality. J Rheumatol. 2012;39:481-485.
69. Grennan DM, Gray J, Loudon J, et al. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis. 2001;60: 214-217.
70. Fuerst M, Mohl H, Baumgartel K, et al. Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Rheumatol Int. 2006; 26:1138-1142.
71. Tanaka N, Sakahashi H, Sato E, et al. Examination of the risk of continuous leflunomide treatment on the incidence of infectious complications after joint arthroplasty in patients with rheumatoid arthritis. J Clin Rheumatol. 2003;9:115-118.
72. Jenks KA, Stamp LK, O'Donnell JL, et al. Leflunomide-associated infections in rheumatoid arthritis. J Rheumatol. 2007;34:2201-2203.
73. Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2012;156:329-339.
74. Dixon WG, Abrahamowicz M, Beauchamp ME, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis. 2012;71:1128-1133.
75. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011;306:2331-2339.
76. Glowniak JV, Loriaux DL. A double-blind study of perioperative steroid requirements in secondary adrenal insufficiency. Surgery. 1997;121:123-129.
77. Jasani MK, Freeman PA, Boyle JA, et al. Cardiovascular and plasma cortisol responses to surgery in corticosteroid-treated R. A. patients. Acta Rheumatol Scand. 1968;14:65-70.
78. Bromberg JS, Alfrey EJ, Barker CF, et al. Adrenal suppression and steroid supplementation in renal transplant recipients. Transplantation. 1991;51:385-390.
79. Friedman RJ, Schiff CF, Bromberg JS. Use of supplemental steroids in patients having orthopaedic operations. J Bone Joint Surg Am. 1995;77:1801-1806.
80. Marik PE, Varon J. Requirement of perioperative stress doses of corticosteroids: a systematic review of the literature. Arch Surg. 2008;143:1222-1226.
81. Shapiro R, Carroll PB, Tzakis AG, et al. Adrenal reserve in renal transplant recipients with cyclosporine, azathioprine, and prednisone immunosuppression. Transplantation. 1990;49:1011-1013.
82. Singh JA, Furst DE, Bharat A, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64:625-639.
83. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-2285.
84. Gilson M, Gossec L, Mariette X, et al. Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor alpha-blockers: a case-control study. Arthritis Res Ther. 2010;12:R145.
85. den Broeder AA, Creemers MC, Fransen J, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol. 2007;34:689-695.
86. Ding T, Ledingham J, Luqmani R, et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford). 2010;49:2217-2219.
87. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762-784.
88. Bykerk VP, Ostor AJ, Alvaro-Gracia J, et al. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Ann Rheum Dis. 2012;71:1950-1954.
89. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis. 2009;68:25-32.
90. Curtis JR, Xi J, Patkar N, et al. Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 2007;56:4226-4227.
91. Greenberg JD, Reed G, Kremer JM, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis. 2010;69:380-386.
92. Kapoor A, Labonte AJ, Winter MR, et al. Risk of venous thromboembolism after total hip and knee replacement in older adults with comorbidity and co-occurring comorbidities in the Nationwide Inpatient Sample (2003-2006). BMC Geriatr. 2010;10:63, 2318-10-63.
93. Schiff RL, Kahn SR, Shrier I, et al. Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis. Chest. 2005;128:3364-3371.
94. Bosque J Jr, Coleman SI, Di Cesare P. Relationship between deep vein thrombosis and pulmonary embolism following THA and TKA. Orthopedics. 2012;35:228, 33; quiz 234-235.
95. Jacobs JJ, Mont MA, Bozic KJ, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Bone Joint Surg Am. 2012;94:746-747.
96. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(suppl 6):381S-453S.
97. Wallberg-Jonsson S, Dahlen GH, Nilsson TK, et al. Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis. Clin Rheumatol. 1993;12:318-324.
98. McEntegart A, Capell HA, Creran D, et al. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford). 2001;40:640-644.
99. Liang KP, Liang KV, Matteson EL, et al. Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations. Arthritis Rheum. 2006;54:642-648.
100. Mont MA, Jacobs JJ. AAOS clinical practice guideline: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Am Acad Orthop Surg. 2011;19:777-778.